Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valneva SE

www.valneva.com

Latest From Valneva SE

More Vaccine Disappointment For Sanofi As First C Diff Toxoid Vaccine Fails

A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.

Vaccines Infectious Diseases

Lyme Disease: Has Big Pharma Stopped The Clock On A Cure?

Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.

BioPharmaceutical Infectious Diseases

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

Financing Business Strategies

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Vivalis
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Valneva SE
  • Senior Management
  • Thomas Lingelbach , Pres. & CEO
    David Lawrence, CFO
    Franck Grimaud, CBO
    Wolfgang Bender, MD, PhD, CMO
  • Contact Info
  • Valneva SE
    Phone: (33) 4 78 76 61 01
    10-12 boulevard Marius Vivier Merle
    Tour Oxygène
    Lyon, 69003
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register